Glycogen synthase kinase-3β in patients with bipolar I disorder: results from a prospective study

Bipolar Disorders

Volumn 18, Issue 4, 2016, Pages 334-341

  Jacoby, Anne S ^a   Munkholm, Klaus ^a   Vinberg, Maj ^a   Joaquim, Helena GP ^b   Talib, Leda L ^b   Gattaz, Wagner F ^b   Kessing, Lars V ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

bipolar disorder; glycogen synthase kinase 3 ; GSK3 ; mania

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM SALT; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; AFFECT; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR MANIA; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED MANIA AND DEPRESSION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 84976636983     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12400     Document Type: Article

References (35)

1. Kessing LV, Hansen MG, Andersen PK. Course of illness in depressive and bipolar disorders. Naturalistic study, 1994-1999. Br J Psychiatry. 2004;185:372–377.
2. Kessing LV. Course and cognitive outcome in major affective disorder. Thesis for Doctor of Medical Science (DMSc), 2001. Dan Med J. 2015;62:B5160, 1-44.
3. Lohoff FW, Berettini WH. Genetics of bipolar disorder. In: Yatham LN, Maj M, eds. Bipolar Disorder: Clinical and Neurobiological Foundations. Singapore: Wiley-Blackwell; 2010:110–123.
4. Kessing LV, Hellmund G, Andersen PK. An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. J Psychopharmacol. 2012;26:644–652.
5. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry. 2011;199:57–63.
6. Severus E, Taylor MJ, Sauer C, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord. 2014;2:15.
7. Fountoulakis KN, Vieta E, Bouras C, et al. A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic? Int J Neuropsychopharmacol. 2008;11:269–287.
8. Andrezza A, Wang JF, Young T. Molecular biology of bipolar disorder. In: Yatham LN, Maj M, eds. Bipolar Disorder: Clinical and Neurobiological Foundations. Singapore: Wiley-Blackwell; 2010:228–243.
9. Du J, Wei Y, Liu L, et al. A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci USA. 2010;107:11573–11578.
10. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem. 1980;107:519–527.
11. Peineau S, Bradley C, Taghibiglou C, et al. The role of GSK-3 in synaptic plasticity. Br J Pharmacol. 2008;153(Suppl 1):S428–S437.
12. Wang H, Brown J, Martin M. Glycogen synthase kinase 3: a point of convergence for the host inflammatory response. Cytokine. 2011;53:130–140.
13. Jope RS. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci. 2011;4:16.
14. Kapczinski F, Vieta E, Andreazza AC, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev. 2008;32:675–692.
15. Kapczinski F, Frey BN, Kauer-Sant'anna M, Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother. 2008;8:1101–1113.
16. Li X, Friedman AB, Zhu W, et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry. 2007;61:216–222.
17. Polter A, Beurel E, Yang S, et al. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology. 2010;35:1761–1774.
18. Ladeira RB, Joaquim HP, Talib LL, Nunes PV, Forlenza OV. Higher proportion of inactive Gsk3beta in platelets of elderly patients with bipolar disorder: an effect of treatment? Rev Bras Psiquiatr. 2013;35:274–278.
19. de Sousa RT, Zanetti MV, Talib LL, et al. Lithium increases platelet serine-9 phosphorylated GSK-3beta levels in drug-free bipolar disorder during depressive episodes. J Psychiatr Res. 2015;62:78–83.
20. Pandey GN, Ren X, Rizavi HS, Dwivedi Y. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment. J Psychiatr Res. 2010;44:143–148.
21. Li X, Liu M, Cai Z, Wang G, Li X. Regulation of glycogen synthase kinase-3 during bipolar mania treatment. Bipolar Disord. 2010;12:741–752.
22. Munkholm K, Lenskjold T, Jacoby AS, et al. Glycogen Synthase Kinase-3beta: variation over time and the possible association with mood and cognition in healthy individuals. Neuropsychobiology. 2016;73:108–115.
23. Munkholm K, Weikop P, Kessing LV, Vinberg M. Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients. Brain Behav Immun. 2015;43:205–213.
24. Munkholm K, Pedersen BK, Kessing LV, Vinberg M. Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology. 2014;47:199–211.
25. Munkholm K, Poulsen HE, Kessing LV, Vinberg M. Elevated levels of urinary markers of oxidatively generated DNA and RNA damage in bipolar disorder. Bipolar Disord. 2015;17:257–268.
26. Munkholm K, Peijs L, Kessing LV, Vinberg M. Reduced mRNA expression of PTGDS in peripheral blood mononuclear cells of rapid-cycling bipolar disorder patients compared with healthy control subjects. Int J Neuropsychopharmacol 2014;18. doi: 10.1093/ijnp/pyu101.
27. Goldstein BI, Young LT. Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function. Curr Psychiatry Rep. 2013;15:425.
28. Wing JK, Babor T, Brugha T, et al. SCAN. Schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiatry. 1990;47:589–593.
29. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278–296.
30. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435.
31. Joaquim HP, Talib LL, Forlenza OV, Diniz BS, Gattaz WF. Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression. J Psychiatr Res. 2012;46:1053–1058.
32. Diniz BS, Talib LL, Joaquim HP, de Paula VR, Gattaz WF, Forlenza OV. Platelet GSK3B activity in patients with late-life depression: marker of depressive episode severity and cognitive impairment? World J Biol Psychiatry. 2011;12:216–222.
33. Gladkevich A, Kauffman HF, Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:559–576.
34. Castri P, Iacovelli L, De Blasi A, et al. Reduced insulin-induced phosphatidylinositol-3-kinase activation in peripheral blood mononuclear leucocytes from patients with Alzheimer's disease. Eur J Neurosci. 2007;26:2469–2472.
35. Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:261–268.